Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 11—November 2020
Research

Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China

Yijun Ding, Yajuan WangComments to Author , Yingfen Hsia, Neal Russell, and Paul T. Heath
Author affiliations: National Center for Children’s Health, Beijing, China (Y. Ding, Y. Wang); University of London, London, UK (Y. Hsia, N. Russell, P.T. Heath); Queen’s University Belfast, Belfast, Northern Ireland, UK (Y. Hsia)

Main Article

Table 2

Proportion of isolates demonstrating antimicrobial resistance in systematic review and meta-analyses of incidence of group B Streptococcus disease in infants, China*

Reference
Publication year
No. isolates
PEN
AMP
CFZ
CAX
VAN
LZD
CHL
ERY
TET
CIP
MXF
LVX
NIT
TGC
Zeng et al. 2013 11 0 0 NT NT 0 0 NT NT 100.0 9.1 9.1 9.1 0 0
Luo et al. 2013 15 0 0 NT 0 0 NT NT 86.7 NT NT NT 0 NT NT
Zheng et al. 2014 12 0 0 NT NT 0 NT NT 16.7 66.7 NT NT NT NT NT
Chen et al. 2014 16 0 0 NT 0 0 NT NT 62.5 NT 25.0 NT 18.8 NT NT
Zhu et al. 2014 13 0 10.0 0 100.0 38.5 0 100.0 100.0 NT 33.3 NT 8.3 0 NT
Fan et al. 2014 42 0 0 NT NT 0 0 NT 69.1 73.8 NT NT 38.1 NT 0
Wang et al. 2015 15 0 20.0 40.0 80.0 0 0 86.7 100.0 NT 26.7 NT 20.0 0 NT
Zhang et al. 2015 6 0 0 83.3 NT 0 0 NT NT NT NT NT NT NT NT
Lei et al. 2015 20 NT 0 NT NT 0 0 25.0 75.0 NT 80.0 NT 70.0 0 NT
Zhang et al. 2015 45 0 2.2 NT NT 0 0 NT 42.2 93.3 0 0 0 NT 0
Cai et al. 2016 15 0 0 NT NT 0 0 NT 46.7 100.0 NT 6.7 6.7 13.3 0
Zhao 2016 28 0 0 NT 0 0 3.6 NT 67.9 NT NT NT 42.9 NT NT
Huang et al. 2016 49 NT NT NT NT NT NT NT 63.3 98.0 11.9 12.2 7.7 NT NT
Liu et al. 2017 15 0 NT NT NT 0 NT NT NT NT NT NT NT NT NT
Zhang et al. 2017 55 0 0 NT NT 0 0 NT 56.6 98.1 1.9 NT NT NT NT
Zhang et al. 2017 15 6.7 0 NT NT 0 0 NT NT 80.0 73.3 73.3 60.0 0 0
Tan et al. 2017 20 0 0 NT NT 0 0 NT NT 100.0 16.7 NT 16.7 NT 0
Zhou et al. 2017 84 4.8 2.4 2.4 0 0 0 4.8 72.6 100.0 35.2 NT 36.9 0 NT
Zhao 2017 45 0 NT NT 0 0 2.2 NT 64.4 NT NT NT 42.2 NT NT
Guan et al. 2018 68 0 NT NT 0 0 0 NT 57.4 95.6 NT NT 5.9 NT NT
Median NA NA 0 0 21.2 0 0 0 55.8 64.4 98.0 25.0 9.1 17.7 0 0
IQI 25% NA NA 0 0 0.6 0 0 0 9.8 56.6 80.0 9.1 3.3 6.9 0 0
IQI 75% NA NA 0 1.7 72.5 60.0 0 0 96.7 75.0 100 35.2 42.8 41.2 0 0

*Values are percentages. Reference details are provided in the Appendix (https://wwwnc.cdc.gov/EID/26/11/18-1414-App1.pdf). Green indicates a rate of AMR <25%; yellow 25%–50%; red >50%; 25%, and 75% refers to AMR interquartile interval of 25% and 75%. Amp, ampicillin; CFZ, cefazolin; CAX, ceftriaxone, CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; IQI, interquartile interval; LZD, linezolid; MXF, moxifloxacin; NA, not applicable; NIT, nitrofurantoin; NT, not tested; PEN, penicillin: TET, tetracycline; TGC, tigecycline; VAN, vancomycin.

Main Article

Page created: August 17, 2020
Page updated: October 17, 2020 10:07 PM EDT
Page reviewed: October 17, 2020 10:07 PM EDT
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external